Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 4, 1996, Pages 1371-1377

  De Boer, Hans ^a   Blok, Geert J ^a   Popp Snijders, Corrie ^a   Stuurman, Lotte ^a   Baxter, Robert C ^b   Van Der Veen, Eduard ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HUMAN GROWTH HORMONE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C;

ADULT; ARTHRALGIA; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MONITORING; EDEMA; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; IMMUNORADIOMETRIC ASSAY; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ADULT; BIOLOGICAL MARKERS; DIHYDROTESTOSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG MONITORING; FOLLOW-UP STUDIES; GROWTH HORMONE; GROWTH HORMONE-RELEASING HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MACROMOLECULAR SUBSTANCES; MALE; PLACEBOS; TESTOSTERONE; THYROXINE; TIME FACTORS; TRIIODOTHYRONINE;

EID: 0029961064     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.4.1371     Document Type: Article

References (48)

1. Cuneo RC, Salomon F, McGauley GA, Sönksen PH. 1992 The growth hormone deficiency syndrome in adults. Clin Endocrinol (Oxf). 37:387-397.
2. De Boer H, Blok GJ, van der Veen EA. 1995 Clinical aspects of growth hormone deficiency in adults. Endocr Rev. 16:63-86.
3. Salomon F, Cuneo RC, Hesp R, Sönksen PH. 1989 The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med. 321:1797-1803.
4. Jorgensen JOL, Pedersen SA, Thuesen L, et al. 1989 Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet. 333:1221-1225.
5. Bengtsson BA, Eden S, Lönn L, et al. 1993 Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 76:309-317.
6. Florini JR, Prinz PN, Vitiello MV, Hintz RL. 1985 Somatomedin-C levels in healthy young and old men: relationship to peak and 24-hour integrated levels of growth hormone. J Gerontol. 40:2-7.
7. Barkan AL, Beitins IZ, Kelch RP. 1988 Plasma insulin-like growth factor-I/ somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab. 67:69-73.
8. Ho KY, Evans WS, Blizzard RM, et al. 1987 Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab. 64:51-58.
9. Blum WF, Albertsson-Wikland K, Rosberg S, Ranke MB. 1993 Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 (IGFBP-3) reflect spontaneous growth hormone secretion. J Clin Endocrinol Metab. 76: 1610-1616.
10. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE. 1979 Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med. 301:1138-1142.
11. Rieu M, Girard F, Bricaire H, Binoux M. 1982 The importance of insulin-like growth factor (somatomedin) measurements in the diagnosis and surveillance of acromegaly. J Clin Endocrinol Metab. 55:147-153.
12. Roelfsema F, Frölich M, van Dulken H. 1987 Somatomedin-C levels in treated and untreated patients with acromegaly. Clin Endocrinol (Oxf). 26:137-144.
13. Ho KY, Weissberger AJ. 1994 Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clin Endocrinol (Oxf). 41:75-83.
14. Bates AS, Evans AJ, Jones P, Clayton RN. 1995 Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-I and urinary growth hormone excretion. Clin Endocrinol (Oxf). 42:417-423.
15. Rosenfeld RG, Wilson DM, Lee PDK, Hintz RL. 1986 Insulinlike growth factors I and II in the evaluation of growth retardation. J Pediatr. 109:428-433.
16. Hasegawa Y, Hasegawa T, Aso T, et al. 1993 Comparison between insulin-like growth factor-I (IGF-I) and the IGF binding protein-3 measurement in the diagnosis of growth hormone deficiency. Endocr J. 40:185-190.
17. Hoffman DM, O'Sullivan AJ, Baxter RC, Ho KY. 1994 Diagnosis of growth hormone deficiency in adults. Lancet. 343:1064-1068.
18. De Boer H, Blok GJ, Popp-Snijders C, van der Veen EA. 1994 Diagnosis of growth hormone deficiency in adults [Letter]. Lancet 343:1645-1646.
19. Janssen Y, van de Berg G, Frölich M, Roelfsema F. Plasma IGF-I and IGFBP-3 in defining the growth hormone status in adults [Abstract A2]. 18th Int Symp on Growth Hormone and Growth Factors in Endocrinol and Metab. 1994; 59.
20. Bates AS, Evans AJ, Jones P, Clayton RN. 1995 Assessment of GH status in adults with GH deficiency using serum growth hormone, serum insulin-like growth factor-I and urinary growth hormone excretion. Clin Endocrinol (Oxf). 42:425-430.
21. Baxter RC, Martin JL. 1986 Radioimmunoassay of growth hormone dependent insulinlike growth factor binding protein in human plasma. J Clin Invest. 78:1504-1512.
22. Baxter RC. 1990 Circulating levels and molecular distribution of the acid-labile (α) subunit of the high molecular weight insulin-like growth factor-binding protein complex. J Clin Endocrinol Metab. 70:1347-1353.
23. r 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: determination by reconstitution and affinity-labeling. Proc Natl Acad Sci USA. 86:6898-6902.
24. Jorgensen JOL, Moller N, Moller J, Weeke J, Blum WF. 1994 Insulin-like growth factors (IGF)-I and -II and IGF binding protein-1, -2 and -3 in patients with acromegaly before and after adenomectomy. Metabolism. 43:579-583.
25. Moller J, Jorgensen JOL, Lauersen T, et al. 1993 Growth hormone dose regimens in adult GH deficiency: effects on biochemical growth markers and metabolic parameters. Clin Endocrinol (Oxf). 39:403-408.
26. Blok GJ, van der Veen EA, Susgaard S, Larsen F. 1991 Influence of concentration and injection volume on the bioavailability of subcutaneous growth hormone: comparison of administration by ordinary syringe and by injection pen. Pharm Toxicol. 68:355-359.
27. Juul, A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE. 1994 The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol (Oxf). 41:85-93.
28. Juul A, Pedersen SA, Sorensen S, et al. 1994 Growth hormone (GH) treatment increases serum insulin-like growth factor binding protein-3, bone isoenzyme alkaline phosphatase and forearm bone mineral content in young adults with GH deficiency of childhood onset. Eur J Endocrinol. 131:41-49.
29. Salmela PI, Juustila H, Pyhtinen J, Jokinen K, Alavaikko M, Ruokonen A. 1990 Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly. J Clin Endocrinol Metab. 70:1193-1201.
30. Ezzat S, Melmed S, Endres D, Eyre DR, Singer FR. 1993 Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocrinol Metab. 76:1452-1457.
31. Laursen T, Jorgensen JOL, Christiansen JS. 1994 Metabolic effects of growth hormone administered subcutaneously once or twice daily to growth hormone deficient adults. Clin Endocrinol (Oxf). 41:337-343.
32. Jorgensen JOL, Moller N, Lauritzen T, Christiansen JS. 1990 Pulsatile versus continous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indices. J Clin Endocrinol Metab. 70:1616-1623.
33. Jorgensen JOL, Blum WF, Moller N, Ranke MB, Christiansen JS. 1991 Short-term changes in serum insulin-like growth factors (IGF) and IGF binding protein 3 after different modes on intravenous growth hormone (GH) exposure in GH-deficient patients. J Clin Endocrinol Metab. 72:582-587.
34. Jorgensen JOL, Flyvbjerg A, Lauritzen T, Alberti KGMM, Orskov H, Christiansen JS. 1988 Dose-response studies with biosynthetic human growth hormone (GH) in GH-deficient patients. J Clin Endocrinol Metab. 67:36-40.
35. Jorgensen JOL. 1991 Human growth hormone replacement therapy: pharmacological and clinical aspects. Endocr Rev. 12:189-207.
36. De Boer H, Blok GJ, Voerman B, de Vries P, Popp-Snijders C, van der Veen E. 1995 The optimal growth hormone replacement dose in adults, derived from bioimpedance analysis. J Clin Endocrinol Metab. 80:2069-2076.
37. Clemmons DR, Van Wyk JJ. 1984 Factors controlling blood concentration of somatomedin C. Clin Endocrinol Metab. 13:113-143.
38. Blum WF, Ranke MB. 1990 Use of insulin-like growth factor binding protein 3 for the evaluation of growth disorders. Horm Res. 33(Suppl 4):31-37.
39. Lee PDK, Hints RL, Sperry JB, Baxter RC, Powell DR. 1989 IGF binding proteins in growth retarded children with chronic renal failure. Pediatr Res. 26:308-314.
40. Hokken-Koelega ACS, Stijnen T, de Muinck Keizer-Schrama SMPF, Blum WF, Drop SLS. 1993 Levels of growth hormone, insulin-like growth factor-I (IGF-I) and -II, IGF-binding protein-1 and -3, and cortisol in prednisone-treated children with growth retardation after renal transplantation. J Clin Endocrinol Metab. 77:932-938.
41. Smith WJ, Underwood LE, Clemmons DR. 1995 Effects of caloric or protein restriction on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in children and adults. J Clin Endocrinol Metab. 80:443-449.
42. Meyer WJ, Furlanetto RW, Walker PA. 1982 The effect of sex steroids on radioimmunoassayable plasma somatomedin C concentrations. J Clin Endocrinol Metab. 55:1184-1187.
43. Caufriez A, Golstein J, Tadjerouni A, et al. 1986 Modulation of immunoreactive somatomedin-C levels by sex steroids. Acta Endocrinol (Copenh). 112: 284-289.
44. Weissberger AJ, Ho KKY, Lazarus L. 1991 Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab. 72:374-381.
45. Liu L, Merriam GR, Sherins RJ. 1987 Chronic sex steroid exposure increases mean plasma growth hormone concentration and pulse amplitude in men with isolated hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 64:651-656.
46. Hobbs CJ, Plymate SR, Rosen CJ, Adler RA. 1993 Testosterone administration increases insulin-like growth factor-I levels in normal men. J Clin Endocrinol Metab. 77:776-779.
47. Jorgensen JOL, Moller N, Lauritzen T, Alberti KGMM, Orskov H, Christiansen JS. 1990 Evening versus morning injections of growth hormone (GH) in GH deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. J Clin Endocrinol Metab. 70:207-214.
48. Johannsson G, Oscarsson J, Johansson JO, Lindstedt G, Lundberg PA, Bengtsson BA. 24-hour variation of serum IGF-I during treatment of growth hormone deficient adults with recombinant human GH [Abstract E6]. 18th Int Symp Growth Hormone and Growth Factors in Endocrinol and Metab. 1994; 115.